Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Obstructive Coronary Artery Disease Clear all
Completed Phase 4 Interventional Results available

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

NCT00862641
View directory record Official record
Conditions
Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
48
States / cities
Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Jun 10, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gadofosveset Trisodium for Heart Imaging Studies

NCT01853592
View directory record Official record
Conditions
Obstructive Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Artery Disease (CAD)
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Arrhythmia Detection In Obstructive Sleep Apnea (ADIOS)

NCT02743520
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia, Stroke, Cardiovascular
Interventions
The Lifestar Act III
Device
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jun 10, 2026, 4:05 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Jun 10, 2026, 4:05 PM EDT
Completed No phase listed Observational

MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR

NCT06139094
View directory record Official record
Conditions
Ischemic Heart Disease, Coronary Microvascular Disease, Angina
Interventions
CardioFlux Magnetocardiography
Device
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Gainesville, Florida • Detroit, Michigan • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Jun 10, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

CORE-COMPARE Pilot Study

NCT06170541
View directory record Official record
Conditions
Coronary Heart Disease (CHD)
Interventions
Aquilion Precision, Conventional Computed Tomography
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 85 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

COVID-19 Testing in Underserved and Vulnerable Populations

NCT05315908
View directory record Official record
Conditions
Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases, COPD, Obesity, Sickle Cell Disease, Diabetes Mellitus, Type 2
Interventions
Community outreach method
Other
Lead sponsor
Jesse Nodora
Other
Eligibility
21 Years and older
Enrollment
9,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jun 10, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

NCT06600178
View directory record Official record
Conditions
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
Interventions
Brezavvy 20Mg Oral Tablet, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

PATient Navigator to rEduce Readmissions

NCT02114515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Heart Failure, Sickle Cell Disease, Myocardial Infarction, Pneumonia
Interventions
Hospital usual care, Navigator intervention, Peer-led telephone support line
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
1,029 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jun 10, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

Determinants of Cardiorespiratory Fitness and Effects of HIIT in Patients With ANOCA Obstructive Coronary Artery Disease(ANOCA)

NCT07182955
View directory record Official record
Conditions
MINOCA, Shortness of Breath, Atherosclerotic Heart Disease of Native Coronary Artery
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 10, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation

NCT02005445
View directory record Official record
Conditions
Obstructive Sleep Apnea, Coronary Heart Disease
Interventions
CPAP, HLSE
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

NCT02147067
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jun 10, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Research Study for Children About Heart Changes and Obstructive Sleep Apnea (OSA)

NCT01837459
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 13 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jun 10, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

mHealth-CArdiac REhabilitation for INOCA

NCT06829160
View directory record Official record
Conditions
Ischemia
Interventions
Communication with exercise therapist, mHealth-CR, Wearable activity monitoring device
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 10, 2026, 4:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
243
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 4:05 PM EDT
Terminated Early Phase 1 Interventional Results available

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

NCT00763035
View directory record Official record
Conditions
Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
Interventions
Regadenoson, Dobutamine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Jun 10, 2026, 4:05 PM EDT
Active, not recruiting Phase 4 Interventional

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

NCT03417388
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2,476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
80
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Catheter-Based Treatment of Cardiovascular Disease

NCT00380016
View directory record Official record
Conditions
Obstructive Coronary Artery Disease, Obstructive Peripheral Artery Disease, Structural Heart Disease
Interventions
Percutaneous Transluminal Angioplasty
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease

NCT00371293
View directory record Official record
Conditions
Sleep Apnea Syndromes, Inflammation
Interventions
Weight Loss Program, CPAP therapy
Behavioral · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jun 10, 2026, 4:05 PM EDT
Completed No phase listed Observational

Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease

NCT01557855
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
Interventions
Corus CAD (ASGES)
Diagnostic Test
Lead sponsor
CardioDx
Industry
Eligibility
21 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Gilbert, Arizona • Tempe, Arizona • Woodstock, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Jun 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional

"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"

NCT01317329
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Hypoxia, Hypercapnia, Sleep Disorders, Obesity, Hypertension, Coronary Artery Vasospasm, Right Ventricular Overload, Left Ventricular Function Systolic Dysfunction, Ventricular Hypertrophy
Interventions
Clinically prescribed CPAP therapy
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jun 10, 2026, 4:05 PM EDT
Active, not recruiting Phase 3 Interventional

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 4:05 PM EDT
Withdrawn Phase 2 Interventional

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

NCT00323024
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
NX1011
Drug
Lead sponsor
NITROX, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2007 · Synced Jun 10, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
Russell Richardson
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 10, 2026, 4:05 PM EDT